No Data
Dongpeng Beverage: Tianjin base construction + channel expansion, gradually increasing market share in the northern region | Direct hitting earnings conference
1. Dongpeng Beverage's "northward" progress has attracted attention, and the company stated that it is actively promoting the construction of the tianjin production base. 2. The company stated that it will gradually increase its market share in the northern market by continuously improving the distribution system, deepening channel expansion, increasing consumer stickiness, and gradually achieving sales conversion.
Humanwell healthcare's "autumn of many events": Controlling shareholder is being applied for reorganization, previously penalized by regulators | Speed Reading Notice
1. Tonight, humanwell healthcare announced that its controlling shareholder Contemporary Technology has applied for restructuring, which has been accepted, there is a possibility of a change in control of humanwell healthcare; 2. Humanwell healthcare, its controlling shareholder Contemporary Technology, and the actual controller have been repeatedly monitored and sanctioned by regulatory authorities; 3. Earlier this year, executives of humanwell healthcare have successively reduced their shareholding, and the 2024H1 performance continues the trend of 'increased revenue but not increased profit' from 2023.
"Miracle drug" for reducing fever – An Gong Niu Huang Wan and Zhangzhou Pientzehuang Pharmaceutical are being recalled in many places, causing a decline in market prices | Industry News
①The price of Angong Niuhuang Pills and Zinc Ingot of Zhangzhou Pientzehuang Pharmaceuticals has dropped, with a decrease of more than 100 yuan per pill/ingot. ②With the production and marketization of cultivated musk in the body, as well as the pilot project of lifting the ban on the import of natural musk in China, industry insiders expect that the tight supply and demand situation of musk raw materials will be alleviated.
Maximum of 6 billion! kweichow moutai proposes to buy back shares, implementing repurchase for the first time in 23 years since listing.
①The purpose of repurchasing shares is for cancellation and reduction of the company's registered capital. ②The repurchase price of shares shall not exceed 1795.78 yuan per share (inclusive).
Is the 'faith' collapsing? kweichow moutai hits a new low in 2022, with many 'top players' reducing their positions.
It is worth noting that Kweichow Moutai fell to 1268.89 yuan in early trading, breaking the previous low of 1333 points before October 31, 2022.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.